Pipeline

February 19, 2018

Company	Drug/Device	Medical Condition	Status
Applied Therapeutics	AT-001	diabetic complications	Phase I trials initiated
Aravive Biologics	AVB-S6-500	n/a	Phase I trials initiated enrolling 40 subjects in the U.S.
Mallinckrodt	ExpressGraftC9T1 skin tissue	diabetic foot ulcers	Phase I trials initiated enrolling six subjects
Pulmatrix	Pulmazole (PUR1900)	allergic bronchopulmonary aspergillosis related to asthma	Phase I trials initiated enrolling 42 subjects
Vyera Pharmaceuticals	TUR-006	toxoplasmosis	Phase I trials initiated
MyoKardia	MYK-491	dilated cardiomyopathy	Phase Ib trials initiated enrolling 64 subjects
Arrowhead Pharmaceuticals	ARO-HBV	chronic hepatitis B virus infection	Phase I/II trials planned enrolling 30 subjects in New Zealand
Audentes Therapeutics	AT342	Crigler-Najjar syndrome	Phase I/II trials initiated
Sienna Biopharmaceuticals	SNA-125	psoriasis and the associated pruritus	Phase I trials initiated enrolling 15 subjects
Imara	IMR-687	sickle cell disease	Phase IIa trials initiated enrolling 50 subjects in the U.S.
Nohla Therapeutics	NLA101	acute myeloid leukemia	Phase II trials initiated enrolling 220 subjects in the U.S.
Citius Pharmaceuticals, Inc.	Mino-Lok Therapy	catheter related bacteremias	Phase III trials initiated enrolling 700 subjects in the U.S.
Intercept Pharmaceuticals	obeticholic acid	cirrhosis due to NASH	Phase III trials planned enrolling 540 subjects
Pfizer	PF-04965842	moderate to severe atopic dermatitis	Breakthrough Therapy designation granted by the FDA
Abeona Therapeutics	ABO-202	infantile Batten disease	Orphan Drug designation granted by the FDA
AstraZeneca, Merck	selumetinib	neurofibromatosis type 1	Orphan Drug designation granted by the FDA
Xeris Pharmaceuticals	ready-to-use glucagon	Hyperinsulinemic Hypoglycemia	Orphan Drug designation granted by the FDA
60 Degrees Pharmaceuticals	Tafenoquine	prevention of malaria	Priority Review designation granted by the FDA
Genentech	Rituxan (rituximab)	pemphigus vulgaris	Priority Review designation granted by the FDA
Janssen	Erleada (apalutamide)	non-metastatic castration-resistant prostate cancer	FDA approved
NorthStar Medical Radioisotopes	RadioGenix System	Non-uranium Sourced Molybdenum-99 Production of Imaging Isotope Technetium-99m	FDA approved